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Nanomaterials in Targeting Cancer
Stem Cells for Cancer Therapy
Weiwei Qin, Guan Huang, Zuanguang Chen* and Yuanqing Zhang*
Institute of Medical Instrument and Application, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou,
China
Cancer stem cells (CSCs) have been identified in almost all cancers and give rise to
metastases and can also act as a reservoir of cancer cells that may cause a relapse
after surgery, radiation, or chemotherapy. Thus they are obvious targets in therapeutic
approaches and also a great challenge in cancer treatment. The threat presented by
CSCs lies in their unlimited proliferative ability and multidrug resistance. These findings
have necessitated an effective novel strategy to target CSCs for cancer treatment.
Nanomaterials are on the route to providing novel methods in cancer therapies. Although,
there have been a large number of excellent work in the field of targeted cancer therapy,
it remains an open question how nanomaterials can meet future demands for targeting
and eradicating of CSCs. In this review, we summarized recent and highlighted future
prospects for targeting CSCs for cancer therapies by using a variety of nanomaterials.
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INTRODUCTION
With the financial support of government and society for cancer research, progress has been made
in the development of innovative strategies for cancer therapy. However, Cancer still remains
one of the deadliest diseases affecting our health, cancer relapse and metastasis are common in
patients accepting traditional chemotherapy or radiotherapy. The failure of traditional therapies
may be ascribed to a relatively rare subpopulation of cancer cells exist in tumor, called cancer
stem cells (CSCs). Since Bonnet and Dick (1997) isolated a small portion of leukemia-initiating
cells with features similar to stem cells, researches seemed to focus on isolating CSCs by specific
identifying markers. Further researches of other tumor types have identified CSCs in almost all
cancers, including prostate (Collins et al., 2005; Maitland and Collins, 2008; Lang et al., 2009), lung
(Eramo et al., 2007), colon (O’Brien et al., 2007; Ricci-Vitiani et al., 2007), pancreatic (Hermann
et al., 2007; Li et al., 2007), gastric (Fukuda et al., 2009), breast (Al-Hajj et al., 2003), glioma (Galli
et al., 2004; Bao et al., 2006), and brain (Hemmati et al., 2003; Singh et al., 2003) cancers. These
CSCs exhibit several characteristics, including self-renewal, differentiation into multiple cell types,
expression of ATP-binding cassette (ABC) pumps that enable them to resist chemotherapeutic
agents, and ionizing radiations.
A variety of nanomaterial, such as DNA (e.g., origami and tetrahedron), carbon (e.g.,
graphene and nanodiamond), noble metal (e.g., gold and silver nanoparticles), organic
polymers, and liposome nanoparticles, with various sizes and modifications to their surfaces
can be easily prepared and offer promising means for developing solutions in CSC therapy
(Tomuleasa et al., 2012; Orza et al., 2013). Nanomaterial is on the route to providing novel
breakthroughs in targeted therapy. During the past decade, nanotechnology and nanomaterial
have been widely integrated in biomedical research, providing new strategies for cell imaging
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(Huang et al., 2006; Kong et al., 2012; Li et al., 2014), siRNA
and drug delivery (Panyam and Labhasetwar, 2003; Lee et al.,
2010; Malmsten, 2013), and targeted cancer therapy (Brannon-
Peppas and Blanchette, 2004; Loo et al., 2005; Bild et al., 2006).
All these mentioned should be attributed to the unique properties
of these nanomaterial, such as high surface to volume ratio,
easiness to be modified, unique optical properties, quantum-size
effects (Whitesides et al., 1991). Taking advantage of and combine
the excellent properties of various nanomaterials will further
provide better solutions for targeted and controlled elimination
of CSCs in the future. The purpose of this review is to summarize
recent progress in the applications of various nanomaterials for
targeting CSCs.
THE BIOLOGY OF CANCER STEM CELLS
Cells that have the ability to self-renewal and generate mature
cells of a specific tissue through differentiation are defined as
stem cells. However, tumorsmay often result from the conversion
of normal stem cells, and similar self-renewal can be regulated
between stem cells and cancer cells including CSCs—a rare,
phenotypically distinct subset of cells that have the capacity to
form new tumors (Hamburger and Salmon, 1977; Figure 1).
Recent studies indicated that normal stem cells in hematopoietic
system are the targets of transforming mutations, and cancer
cell proliferation is driven by CSCs. CSC and normal stem cell
share a lot of properties. And the most important one is that
both of them have unlimited potential (Reya et al., 2001) for
self-renewal that promote tumorigenesis and give rise to new
(normal or abnormal) tissues. Moreover, CSCs (self-renewal
either inherent or acquired) can produce cells that lack long-
term self-renewal ability but preserve dividing capability. Thus,
CSCs can be thought of as tumorigenic cells that go through an
anomalous and scanty regulated process of tumorigenesis, which
is similar to what normal stem cells do.
THE NECESSITY OF TARGETING CANCER
STEM CELLS
Cancer cells can acquire resistance to conventional approaches
for cancer treatment such as chemotherapy and radiotherapy
(Dean et al., 2005; Eyler and Rich, 2008) by a variety of
mechanisms (Dean et al., 2005), including the mutation or
overexpression of the drug target, inactivation of the drug, or
elimination of the drug from the cell. Drug resistance and
cancer metastasis are the two primary problems for the therapy
of cancer. Recent studies indicated that endothelial cells can
protect normal stem cells and cancer cells from radiation damage
(Garcia-Barros et al., 2003; Bao et al., 2006; Diehn and Clarke,
2006). On the basis of CSCs concept, an alternative model posits
that the CSCs are naturally resistant to chemotherapy through
their quiescence, ABC-transporter expression, and their capacity
for DNA repair as they self-renewal, which allow them to expand
the population of tumor cells following with chemotherapy
or radiotherapy. Furthermore, the survival of residual CSCs is
thought to be one of the factors that drives the onset of tumor
recurrence, distant metastasis, and drug-resistance, which is a
significant clinical problem for the effective treatment of cancer.
Conventional chemotherapeutic agents are not only uneasily
to accept but also unable to destroy the drug-resistant CSCs,
thus it demands a novel approach for cancer therapy. If the
chemotherapeutic agents used can efficiently target against CSCs
(Stupp and Hegi, 2007), then it might be more effective in killing
them. Since more and more efficiently new diagnostic markers
(such as, CD44+, CD90+, CD133+, and so on) and therapeutic
targets expressed by the stem cells have been found, solid CSCs
can be identified prospectively and isolated efficiently. Thus,
CSC-based therapies may don’t remit cancers at the beginning,
but they may eventually cure cancers successfully.
APPLICATIONS OF NANOMATERIALS FOR
CSC TARGETING
Nanomaterials have attracted much attention during the past
few decades and will attract more attention in the future owing
to their unique optical, chemical, and electronic properties
(Manchikanti and Bandopadhyay, 2010; Chen et al., 2013). On
the basis of these unique properties, they have been applied in
a wide spectrum of fields, including catalysis (Thompson, 2007;
Luo et al., 2010; Diao and Cao, 2011; Zheng et al., 2011; Li
et al., 2015), plasmonic imaging (Li et al., 2013; Peng et al.,
2015), biochemical sensors (Orza et al., 2010; Zheng et al., 2011;
Qin et al., 2015; Xu Y. et al., 2015), tumor cell detection (Lu
et al., 2010), targeted therapy (Kumar et al., 2012), and so
on. The unique characteristics of nanomaterials mainly benefit
from their high surface to volume ratio compared with their
respective bulk counterparts. The large quantities of surface
atoms of nanomaterials enable them to have outstanding surface
properties that can be utilized for the modification of anti-cancer
drugs, various active agents, and targeting molecules commonly
used in cancer therapy. Scheme 1 summarizes the mechanisms
of the engineered nanoparticles for drug delivery in cancer stem
cell therapy. In combination with the latest findings in the area
of CSC researches, nanomaterials will bring new opportunities in
detecting and targeting of CSCs.
CARBON NANOMATERIALS IN CSC
TARGETING
During the last decade, carbon nanotechnology has achieved
rapid development, allotropes of carbon, especially graphene,
diamond and carbon nanotubes, have found a wide range of
applications in industry and biomedicine. Carbon nanomaterials
have also attracted extensive attention from clinical scientists
in frontier research and they were used as potential agents in
anticancer therapies.
GRAPHENE OXIDE
Graphene began to attract widespread attention since single
layers of graphite were obtained by Novoselov et al. (2004) and
it was regarded as the most promising material for transistor
Frontiers in Pharmacology | www.frontiersin.org 2 January 2017 | Volume 8 | Article 1
Qin et al. Nanomaterials in Targeting Cancer Stem Cells
FIGURE 1 | Cancer stem cells and tumor progression. Normal stem cells give rise to multipotent progenitor cells, committed progenitors and mature,
differentiated cells. Mutations in a stem cell give rise to a stem cell with aberrant proliferation and result in a pre-malignant lesion. Additional mutations lead to the
acquisition of further increased proliferation, decreased apoptosis, evasion of the immune system, and further expansion of the stem-cell compartment that is typical
of malignant tumors (Dean et al., 2005).
production that could replace traditional semiconducting
materials. Graphene oxide (GO) is a graphene derivative with
carbon atoms linked to oxygen functional groups which confers
an extraordinary chemical versatility. Thus, the surface of
graphene can be easily modified with various biochemical
molecules and agents of interest, which enable graphene an
excellent carrier of drugs or nucleic acids for targeted cancer
therapies.
Previous studies have shown that GO can be used for targeted
cancer therapies, prevent tumor growth and inhibit tumor cell
migration (Tian et al., 2011; Gonçalves et al., 2013; Gurunathan
et al., 2015). In 2014, Jung et al. reported a photothermal
therapy based on transdermal nano-graphene oxide-Hyaluronic
acid (NGO-HA) conjugates for melanoma skin cancer by using
near-infrared (NIR) laser. Because the melanoma tissues of mice
are relatively leaky and express high levels of HA receptors,
thus NGO-HA could easily penetrate and retain in the tumor
tissues for ablating tumor efficiently without recurrence (Jung
et al., 2014). However, studies that exploited GO in CSC
therapy for cancer treatment is rare. Fiorillo et al. demonstrated
that GO is efficient in inhibiting tumor-sphere formation in
six independent cancer cell lines, across multiple tumor types
(prostate, ovarian, breast, lung, pancreatic, and brain cancer).
They employed the tumor sphere assay, which functionally
measures the tumor sphere formation and expansion from single
CSCs under anchorage-independent conditions, to evaluate the
GO-targeted therapy. The obtained results suggested that GO
specifically targets a global phenotypic property of CSCs and
it may reduce the number of bonafide CSCs by inducing their
differentiation and inhibiting their proliferation (Figure 2A,
Fiorillo et al., 2015). In a word, the author here present evidence
that GO based therapy may be effective in exterminating CSCs
by inhibiting several key signal pathways and then inducing CSC
differentiation.
CARBON NANOTUBES
Carbon nanotubes are cylindrical graphene nanostructures with
unique properties, such as water-solubility, cell membrane
penetrability, high drug-loading ability, selective retention in the
tumor, low toxicity, photothermal, photoacoustic, and Raman
properties which are valuable for nanotechnology and clinical
research (Shao et al., 2013; Wu et al., 2014). In 2012, Burke et al.
demonstrated that breast cancer stem cells (BCSCs) are sensitive
to carbon nanotube-mediated thermal treatment and lose
their long-term proliferative capacity after nanotube-mediated
thermal therapy (Burke et al., 2012). Therefore, the nanotube-
mediated thermal treatment can simultaneously eliminate both
the differentiated cells that constitute the bulk of a tumor and the
BCSCs that drive tumor growth and recurrence. In 2014, a gastric
CSCs-specifically targeting drug delivery system (SAL-SWNT-
CHI-HA complexes) based on chitosan(CHI) coated single wall
carbon nanotubes (SWNTs) loaded with salinomycin (SAL)
functionalized with hyaluronic acid (HA) were fabricated by
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SCHEME 1 | The mechanisms of the engineered nanoparticles for drug delivery in cancer stem cell therapy. A summary of nanoparticles that have been
explored as carriers for drug delivery in cancer stem cell therapy, together with illustrations of biophysicochemical properties.
FIGURE 2 | (A) Graphene oxide (GO): Targeting cancer stem cells with differentiation-based nano-therapy. The current mechanistic studies suggest that GO could
directly be used as a therapeutic for targeting cancer stem cells (CSCs), because of its ability to induce differentiation. In this context, we might envision that GO could
be used to clear residual CSCs, with the aim of preventing tumor recurrence and distant metastasis, thereby providing a practical means for achieving
“differentiation-based nano-therapy” (Fiorillo et al., 2015); (B) Schematic illustration of the preparation process of SAL-SWNTs-CHI-HA [chitosan(CHI) coated single
wall carbon nanotubes (SWNTs) loaded with salinomycin (SAL) functionalized with hyaluronic acid (HA); Yao et al., 2014]; (C) Schematic diagram illustrating the
concept of functionalized SWCNTs as drug carriers (Al Faraj et al., 2016b); (D) Left: schematic model showing surface and chemical structure of (ND) and Epirubicin
(Epi), synthesis and aggregation of Epirubicin-nanodiamond complex (EPND). ND represented in truncated octahedron structure with different surface charge denoted
with color. ND surface functional group indicated, including benzene ring, carboxyl group, and hydrogen group. Molecular skeleton representing carbon, oxygen and
nitrogen atoms in Epi molecule was shown in red. Synthesis of EPND was performed under basic condition of 2.5 mM NaOH through physical adsorption between
Epi and ND. Aggregation around 90 nm was formed after EPND synthesis. Right: representative image shows that EPND can inhibit tumor-initiation in murine hepatic
tumor allografts (Wang et al., 2014).
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Yao et al. The constructed system was shown to have ability to
selectively eliminate gastric CSCs (Figure 2B, Yao et al., 2014).
Al Faraj et al. developed a strategy that employed biocompatible
multimodal SWCNTs functionalized with CD44 antibodies and
confirmed the enhanced selective targeting of anti-CD44, which
provided encouraging results for efficient targeting of breast
CSCs and perspectives for further clinical studies (Al Faraj et al.,
2016a). Soon afterwards, the same group combined Paclitaxel and
Salinomycin drugs conjugated SWCNTs (Figure 2C) to actively
target both breast cancer and CSCs in xenograft murine model
and the results confirmed the enhanced therapeutic effect of
the combined therapy compared to treatment with individual
drug-conjugated nanocarriers or free drug suspensions. Thus,
the developed conjugated SWCNTs drug delivery system holds
great promise for effective breast cancer therapy by targeting both
cancer cells and CSCs (Al Faraj et al., 2016b).
NANODIAMOND
Nanodiamonds are truncated semi-octahedral carbon structures,
and the surface of which can be functionalized with a wide variety
of biological and chemical agents, including small molecules,
therapeutic and targeting biomolecules, genetic material as well
as imaging agents (Liu et al., 2009). Among a wide variety
of nanomaterials-based vehicles, nanodiamonds (NDs) have
shown outstanding delivery ability and excellent biocompatibility
(Zhang et al., 2016). Zhao et al. have demonstrated that
detonation nanodiamond with hyperbranched polyglycerol
coating (dND-PG) loaded with anticancer drug and led by
efficient targeting moiety can realize highly preferential toxicity
to the intended tumor cells through specific uptake mechanisms,
while with minimum uptake and toxicity in macrophages
(Zhao et al., 2014). Nanodiamond-drug complex by physical
adsorption of Epirubicin on nanodiamonds was also fabricated
and was demonstrated to be a highly effective nanomedicine-
based approach to overcome chemoresistance in hepatic CSCs.
As shown in Figure 2D, the resulting Epirubicin@nanodiamonds
complex, EPND, possesses enhanced treatment compared with
unmodified Epirubicin (Wang et al., 2014). The ability to attach
various bioactive molecules, including cell-specific ligands, to
carbon molecules enables carbon-based nanomaterials to be an
efficient solution for cancer therapy by targeting CSCs.
DNA ORIGAMI FOR TARGETING CSCs
DNA self-assembling nanostructure (Lanier and Bermudez,
2015; Kim et al., 2016; Xia et al., 2016), especially DNA origami,
has been considered as the most promising candidates as a
drug delivery carrier for cancer therapy (Zhao et al., 2012;
Ouyang et al., 2013; Zhu et al., 2013; Zhang et al., 2014; Jiang
et al., 2015; Zhuang et al., 2016). DNA origami were prepared
through the self-assembly of a long single stranded M13mp18
phage DNA and hundreds of complementary short DNA staples,
which endows the structure with high levels of structural
programmability, obvious biocompatibility, and easiness to be
modified with functional moieties. Furthermore, DNA origami
can be functionalized with the agents of interest with high spatial
precision, the so called “addressability.” With the aid of this
technology, nanoscale assemblies of drugs and other active agents
can be organized with unprecedented precision and with high
load for targeted therapies.
In 2012, Jiang et al. reported a drug delivery system
(Figure 3A) based on triangular and tubular DNA origami
nanostructures, which are spatially addressable, of high loading
capacity and good biocompatibility. Then, doxorubicin were
loaded in these structures and administered to human breast
cancer cell line MCF-7 cells and the effective internalization
of the structure by both cell lines were confirmed by confocal
fluorescent analyses. The origami-doxorubicin complex
exhibited prominent cytotoxicity not only to regular human
breast cancer cells (MCF 7), but more importantly to
doxorubicin-resistant cancer cells, inducing a remarkable
reversal of phenotype resistance. Then, the authors studied the
means by which the DNA origami-drug complex circumvents
resistance in res-MCF 7 cells. The results indicated that the DNA
nanostructure delivery platform circumvented drug resistance in
res-MCF 7 cells by increasing the cellular uptake of doxorubicin
and inducing a change in lysosomal pH that redistributed the
drug to target sites (Jiang et al., 2012). Halley et al. synthesized
a rod-like DNA origami drug carrier (Figure 3B) that can
be controllably loaded with daunorubicin and demonstrated
the ability of the DNA origami-drug complex to circumvent
eﬄux-pump-mediated drug-resistance of leukemia cells. Their
results directly showed that DNA origami-based daunorubicin
delivery had the potential to treat acute leukemia cells exhibiting
multi-drug resistance (MDR). In addition, the results revealed
that circumvention of MDR could be achieved at concentration
ranges of 0.1–1.0 µmol/L daunorubicin. What’s more, they
found that it is crucial to control the quantities of drug loaded in
origami to maximize the drug efficacy, especially in disrupting
cellular proliferation (Halley et al., 2016).
Nowadays, it is simple to synthesize various DNA origamis
with a series of geometric and aesthetic shapes (triangle,
rectangle, pillar, and so on) with diverse dimensions (1D, 2D,
and 3D) using rational design principles. In addition, the fully
addressable DNA origami nanostructures can be produced in
extremely high yields and a wide range of molecules and
nanoparticles can be functionalized on the nanostructures
through hundreds of addressable staples. What’s more, it is
suggested that DNA origami were of excellent stability in cell
lysate, which is of great significance for drug delivery and
controlled drug release. All these properties enable DNA origami
structures a promising tool in biomedical fields, especially in
cancer nanotechnology. We believe that DNA origami has
unlimited potential and will play important roles in cancer
therapies in the future.
GOLD NANOPARTICLES FOR TARGETING
CSCs
Gold nanoparticles [e.g., Au NPs and gold nanorods (Au NRs)]
have been widely used in cancer research (Wang et al., 2011;
Frontiers in Pharmacology | www.frontiersin.org 5 January 2017 | Volume 8 | Article 1
Qin et al. Nanomaterials in Targeting Cancer Stem Cells
FIGURE 3 | (A) DNA origami and doxorubicin origami delivery system assembly. The long single-strand M13mp18 genomic DNA scaffold strand (blue) is folded into
the triangle and tube structures through the hybridization of rationally designed staple strands. Watson−Crick base pairs in the double helices serve as docking sites
for doxorubicin intercalation. After incubation with doxorubicin, the drug-loaded DNA nanostructure delivery vessels were administered to human breast cancer cell
line MCF 7 cells, and the effects were investigated (Jiang et al., 2012); (B) Top: Transmission electron microscope (TEM) images of the designed DNA origami
structure; Bottom: The number of viable cells subjecting to free daunorubicin or daunorubicin-loaded Horse nanostructures for 24 h (Halley et al., 2016). *p < 0.05.
Chen et al., 2012; Iodice et al., 2016) by the reason of their
facile synthesis, easiness for functionalization, localized surface
plasmon resonance, and excellent biocompatibility (Huang and
El-Sayed, 2010). In fact, it has been well-established that Au
NPs are biocompatible (non-cytotoxic and non-immunogenic),
which is very important for the widespread applications in
nanomedicine and drug delivery (Ghosh et al., 2008; Brown
et al., 2010; Kong et al., 2016). All these properties enable them
very suitable for clinical research (Lee et al., 2011; Tiloke et al.,
2016). Nowadays, sphere Au NPs (Sun and Xia, 2002) of different
diameters can be synthesized in high quality and high yield
by the well-known citrate reduction method. The progress of
synthetic chemistry in the last decade enables Au NPs of different
shapes (Murphy et al., 2005; Xia et al., 2009) and sizes to be
synthesized, including Au NRs (Jana et al., 2001; Nikoobakht
and El-Sayed, 2003), gold nanoflowers (Xie et al., 2008; Wang
et al., 2010), gold nanocages (Skrabalak et al., 2008; Xia et al.,
2011), and so on. The radiative properties of gold nanoparticles
including absorption, scattering and localized surface plasmon
resonance (LSPR) make them very suitable for photothermal
therapy and molecular cancer imaging. While the easiness for
surface modification enables them very suitable for drug delivery
(Tian et al., 2016) and cancer therapies.
SPHERE AU NPs
The unique physico-chemical properties of Au NPs have been
used for targeted drug delivery (Ghosh et al., 2008; Elbialy
et al., 2015) in almost all cancer types and have demonstrated
enhanced anti-tumor efficacy (Patra et al., 2010; Wagstaff et al.,
2012; Setua et al., 2014). However, the discovery of CSCs has
changed the direction of the targeted chemotherapy and directs
the anti-cancer research toward targeting CSCs (Atkinson et al.,
2010; Sun et al., 2014a,b; Gilam et al., 2016; Yi et al., 2016).
Tomuleasa et al. reported a novel strategy based on
functionalized AuNPs for Hepatocellular carcinoma and lowered
the chemoresistance of Hepatocellular Carcinoma Cells. They
first stabilized Au NPs with a monolayer of L-aspartate and then
additional drugs (e.g., doxorubicin, cisplatin, and capecitabine)
were conjugated through non-covalent interaction to obtain the
drug complex. Tumor-targeting results suggested that the cellular
proliferation in the presence of the anti-cancer drugs complex
prepared from the Au NPs were repressed compared with those
of cells exposed to the cytostatic drugs alone, indicating that
Au NPs increased the susceptibility of Hepatocellular Carcinoma
Cells to these drugs (Tomuleasa et al., 2012). Cancer cells
undergo faster metabolism and consume more glucose than
normal cells, taking advantage of this property, Hu et al. chose
glucose as a reagent to target cancer cells. Au NPs modified
with thio-PEG (polyethylene glycol) and thio-glucose (Glu-Au
NPs) was created for targeted treatment of cancer metastasis
and CSCs. Using human monocytic cell line derived from acute
monocytic leukemia patients as a model (due to its properties
are similar to CSCs), and then fed the cells with Glu-Au
NPs followed by X-ray irradiation. The experimental results
show that Glu-Au NPs enhanced the elimination of human
monocytic cells 20% more than X-ray irradiation alone and Au
NP treatment alone (Hu et al., 2015). Kouri et al. synthesized
Au NPs modified with mature miR-182 duplexes [miR-182-
based spherical nucleic acids (182-SNAs), Figure 4A] and
injected 182-SNAs intravenously to the orthotopic Glioblastoma
multiforme (GBM) xenografts. The results showed that 182-
SNAs could penetrate the blood–brain/blood–tumor barriers
and selectively disseminate throughout extravascular glioma
parenchyma, leading to shrinked tumor size and increased
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FIGURE 4 | (A) miR-182 or Co-miR–RNA duplexes were hybridized to citrate stabilized gold nanoparticles (Au NPs) via thiol-gold bond and passivated with
polyethylene glycol-Thiol (mPEG-SH) to obtain miR-182-based spherical nucleic acids (182-SNAs); (B) Analysis of tumor burden by weight and (C) bioluminescence
imaging; (A–C) (Kouri et al., 2015); (D) Top: fabrication of polyelectrolyte conjugated Au NRs and drug loading; Bottom: schematic illustration of selective elimination of
breast cancer stem cells (CSCs) by polyelectrolyte conjugated gold nanorods (Au NRs) mediated hyperthermia. CTAB, cetyltriethylammnonium bromide; PAA,
Poly(acrylic acid); PDC, poly-diallyldimethylammonium chloride; ALDH+, aldehyde dehydrogenase positive (Xu et al., 2014).
survival rates (Figures 4B,C). The authors, here, present a novel
strategy for therapeutic intervention in GBM by exploiting the
anti-tumor activities of miR-182 which was modified on Au NPs
to form spherical nucleic acids (Kouri et al., 2015).
GOLD NANORODS (AU NRs)
Compared with Au NPs, Au NRs have greater advantages in
cancer cell imaging and photothermal therapy based on their
localized surface plasmon resonance (LSPR) at near-infrared
(NIR) wavelength band (Oli, 2010; Peng and Wang, 2011). One
of the advantages of Au NRs is that the light source used for
imaging and photothermal therapy can be NIR wavelength band
which induce less damage and possess better tissue penetrability.
Therefore, Au NRs has been widely used in cancer research,
especially in photothermal therapy (Amreddy et al., 2015; Liu
et al., 2016).
Wang et al. reported a strategy by using aptamer-modified
Au NRs for targeted photothermal therapy of prostate CSCs.
In this work, two kinds of aptamers [against DU145 prostate
cancer cells (aptamer CSC1) and against prostate CSCs (aptamer
CSC13)] were modified on the surfaces of Au NRs, and the
obtained Au NRs complex successfully targeted and destructed
both cancer cells and CSCs through NIR laser irradiation (Wang
et al., 2013). Xu et al. found that photothermal therapy mediated
by Au NRs can selectively eliminate breast CSCs (Xu et al.,
2014). The results suggested that polyelectrolyte conjugated Au
NRs treatment reduced the aldehyde dehydrogenase positive
(ALDHþ) cells subpopulation, the gene expression of stem
cell markers and the mammosphere forming ability. Cellular
uptake assay suggested that one of the possible reasons for the
selective elimination of CSCs is they could internalize much
more and faster of the conjugated Au NRs. The authors further
combined the chemotherapy and photothermal therapy, loading
the polyelectrolyte conjugated Au NRs with salinomycin (SA),
and obtained enhanced inhibition of CSCs (Figure 4D).
The combination of multiple therapies for cancer treatment
has already been inevitable and is also a general tendency. The
development and integration of materials science, bioimaging,
and cancer biology has now enabled the design of stimuli-
responsive intelligent platforms for cancer therapies (Conde
et al., 2015). In 2016, Conde et al. developed a triple-integration
therapy, a combination of gene therapy, drug therapy and
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photothermal therapy, to remit non-resected tumor, and prevent
tumor recurrence after the tumor excision surgery (Conde
et al., 2016). They loaded hydrogel with Au NRs@drug (for
chemotherapy and photothermal therapy) and Au NPs@siRNA
(for Kras gene silencing) for triple therapies (Figure 5A), while
the hydrogel was used to stabilize the integral delivery system
and enable local delivery of the conjugates. In the same year,
Kong et al. prepared a biocompatible double emulsion system
with higher integration degree, which integrated porous silicon
nanoparticles (PSi NP), Au NRs, DNA origami, antibody,
doxorubicin, 17-AAG or Rapamycin, and Erlotinib or Afatinib
in one platform; (Kong et al., 2016; Figure 5B). The all-in-one
system could overcome multidrug resistance and enable more
effective treatments of cancer, thus it holds great potential in
biomedical field for cancer therapy.
Au NPs are potential nanomaterials to be utilized in CSCs
targeting for the following reasons: firstly, they can be easily
synthesized a wide variety of sizes and shapes; secondly,
they are very stable, of highly biocompatibility and easily to
be functionalized with various bioactive agents; Thirdly, they
possess unique optical properties and are easily tracked and
detected by absorption/scattering spectroscopy.
ORGANIC NANOPARTICLES FOR
TARGETING CSCs
Liposomes, polymeric nanoparticles, and dendrimers have been
the most widely studied carriers in the field of nanoscale
drug delivery (Duncan and Gaspar, 2011). Why they are so
popular? First, they hold high stability and good biocompatibility
both in vitro and in vivo, and can solubilize a wide
range of poorly soluble drugs. Polymeric nanoparticles are
commonly prepared from natural polymers (such as chitosan)
or synthetic biocompatible polymers [such as poly-lactic-co-
glycolic acid (PLGA)], while liposomes, analogs of biological
membranes, have always been regarded as one of the most
biocompatible vehicles for drug delivery (Colson and Grinstaff,
2012; Hadinoto et al., 2013; Mandal et al., 2013; Crucho, 2015).
In addition, polyethylene glycol (PEG) is usually conjugated to
the polymer nanoparticles to enhance the immune-compatibility.
Second, they can avoid the short time drug degradation after
administration. Third, they can also prevent undesirable side
effects on normal cells, organs, and tissues by some cytotoxic
drugs. The last but not the least, they can increase drug
bioavailability and the fraction of the drug accumulated in
the pathological area. A variety of drug delivery and drug
targeting systems, such as synthetic polymers(Chenna et al.,
2012; Usacheva et al., 2014; Kumar et al., 2015), microcapsules
(Chen et al., 2015), lipoproteins (Helbok et al., 2012; Shen et al.,
2016), liposomes (Yuan et al., 2013; Han et al., 2014; Lokerse
et al., 2016), lipid particles(You et al., 2015), and many others
have been designed and exploited for cancer therapy (Torchilin,
2006). Therefore, they hold great potential to generate practical
strategies for the CSC therapy in the near future.
LIPOSOME
A liposome is a spherical vesicle that composed of at least one
lipid bilayer and it can be used as a vehicle for delivering drugs.
Liposomes can ameliorate the stability and pharmacokinetics of
free drugs and furthermore improve the safety and efficiency
of them, but the therapeutic efficacy of them has not been
sufficiently enhanced. Compared with non-targeted liposome,
targeted treatment of cancer cells, especially the CSCs, do hold
FIGURE 5 | (A) Drug–gold nanorods and siRNA–gold nanospheres doped in implantable hydrogels for local drug/gene delivery and local hyperthermia (Conde et al.,
2016). (B) Schematic illustration of the preparation of biocompatible porous silicon nanoparticles@gold nanorods@double emulsion (PSi NPs@AuNRs@double
emulsion) co-delivery platform for co-loading versatile therapeutics, DNA origami, antibody, and hydrophobic functional PSi NPs loaded with Erlotinib or Afatinib (Kong
et al., 2016).
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FIGURE 6 | (A) Post-insertion method for the preparation of CD44-doxil (Arabi et al., 2015). (B) The preparation procedure of salinomycin-loaded PEGylated
poly(lactic-co-glycolic acid) nanoparticles (SAL-NP) or SAL-NP linked with CD133 aptamers (Ap-SAL-NP; Ni et al., 2015).
great potential to improve the therapeutic index, and decrease the
influence of off-target phenomenon.
Liu et al. first synthesized a liposome involving antialcoholism
drug disulfiram (shorted for lipo-DS) combined with copper
in vivo, aiming to target CSCs and avoid pan-chemoresistance
(Liu et al., 2014). Lipo-DS targeted NFκB pathway, that
promote hypoxia-induced CSCs and these fabricated Lipo-
DS/CuGlu (copper gluconate) showed a strong anti-CSC
efficacy. In the following year, Shen et al. fabricated a novel
Nano-Taxol (encapsulated paclitaxel in liposome), and then
investigated its effects on the stem ness phenotype and metabolic
reprogramming of CSC (Shen et al., 2015). They found that
intraperitoneal administration of Nano-Taxol influenced the
metabolic reprogramming of cells, from glycolysis to oxidative
phosphorylation and effectively suppressed CSCs. Compared
with intravenous delivery of Taxol? (current standard treatment),
Nano-Taxol showed a significantly better control of tumor
growth. This research may provide a new approach for the
nanomedicine development. In the near future, this method
can be applied to the treatment of several relevant cancers that
have been proved to be suitable for local delivery of therapeutic
agents, including colon cancer, gastric cancer, and pancreatic
cancer. In 2015, Basak et al. demonstrated that delivery of
Curcumin-difluorinated (CDF) liposomes was a useful method
for cisplatin resistant Head and neck squamous cell carcinoma
(HNSCC) therapy (Basak et al., 2015). CDF, synthesized from
the curcumin and wrapped with liposomes, was applied to
evaluate the growth inhibition of cisplatin resistant HNSCC
cell lines CCL-23R and UM-SCC-1R, and showed significant
growth inhibition in these drug-resistant cell lines. Then, Arabi
et al. constructed monoclonal antibody (mAb) modified doxil
(Figure 6A), which would not damage the biodistribution of a
long-circulating carrier, and used it to target CD44, one of the
most well-known surface markers related with CSCs. The result
indicated the potential of anti-CD44 mAb in the improvement
CSC therapy (Arabi et al., 2015).
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ANV-1 was a liposomal formulation for carrying
anticancer drug to breast cancer stem-cell-like cells, and its
pharmacokinetics in an animal model also had been evaluated.
The anticancer drug ESC8 connected with dexamethasone
(Dex)-associated liposome (DX) to form ESC8-entrapped
liposome named DXE. The results showed DXE was a promising
liposomal formulation with potent pharmacokinetic and
tumor regressing profile that could sensitize and kill highly
aggressive and drug-resistive tumor progenitor cells (Ahmad
et al., 2016). Since liposomes provide a biocompatible and
biodegradable container for loading drugs and the surface
of which can be modified with various targeting ligand, they
hold great possibility to deliver drugs for targeted cancer
therapy.
POLYMER NANOPARTICLES
Targeting cancer metabolism is emerging as a successful
strategy for cancer therapy. In 2012, Xu et al. constructed
NanoHHI (nanoparticle-encapsulated inhibitor of the hedgehog
transcription factor) by the oil-in-water (o/w) emulsion solvent
evaporation method that loaded PLGA-PEG (poly(lactic-co-
glycolic acid) - polyethylene glycol) nanoparticles with HPI-
1 (Xu et al., 2012). NanoHHI significantly suppressed the
growth of both Huh7 and MHCC97L cells, decreased the
population of CD133-positive hepatocellular carcinoma cells
(HCC). Thioridazine (THZ), which was reported to have
ability to kill CSCs, was combined with doxorubicin (DOX)
to eradicate both cancer cells and DOX-resistant CSCs to
mitigate the cancer relapse (Ke et al., 2014). The micelles
were self-assembled from a mixture of acid-functionalized poly
(carbonate) and poly(ethylene glycol) diblock copolymer (PEG-
PAC) and urea-functionalized poly(carbonate) (PUC) and PEG
diblock copolymer (PEG-PUC). Co-delivery of free DOX and
THZ with the micelles showed strong inhibitory effect against
cancer cells and CSCs. This combination therapy can target
both cancer cells and CSCs offered a favorable strategy for
breast cancer therapy. In 2015, Ni et al. developed nomycin-
loaded nanoparticles to eliminate CD133+ osteosarcoma CSCs
(Ni et al., 2015). Then, salinomycin-loaded PEGylated poly
(lactic-co-glycolic acid) nanoparticles (SAL-NP) connected with
CD133 aptamers (Ap-SAL-NP) (Figure 6B) were constructed
by the method of emulsion/solvent evaporation. The results
suggested that CD133, a well-known surface marker in CSCs,
was a prospective target for drug delivery to osteosarcoma CSCs
and that it is potential to significantly inhibit the osteosarcoma
growth by killing CD133+ osteosarcomal CSCs.
In 2013, Swaminathan et al. synthesized poly(D,L lactide-co-
glycolide) nanoparticles modified with anti-CD133 monoclonal
antibody and paclitaxel, a microtubule-stabilizing anticancer
agent, to target CD133+ cells (Swaminathan et al., 2013). CD133-
targeted nanoparticles (CD133NPs) were effectively engineered
to target cells which abundantly express CD133, and the NPs
show significant suppression of Caco-2 cells, decreasing the
number of mammospheres and colonies formed compared with
the free paclitaxel treatment. Nanogel-drug conjugates based on
membranotropic cholesteryl-HA (CHA) were also developed by
Wei et al. for efficient targeting and suppressing drug-resistant
tumors (Wei et al., 2013). The conjugates significantly increased
the solubility and bioactivities of poorly soluble drugs, such
as etoposide, salinomycin, and curcumin against CSC. These
nanogels were efficiently internalized via CD44 receptor and
was shown to be capable of penetrate multicellular cancer
spheroids and displayed higher cytotoxic effect in the system
modeling tumor environment than both free drugs and HA-
drug conjugates. Cationic lipid-assisted poly(ethylene glycol)-
b-poly(d,L-lactide) (PEG-PLA) nanoparticles, can efficiently
deliver siRNA into U87MG and U251 glioma stem cells
and bulk glioma cells, simultaneously inhibited the self-
renewal of these cells in a glucose restricted tumor micro-
environment. PEG-PLA Nanoparticles with specific siRNA
targeting GLUT3 (NPsiGLUT3) significantly reduced the GLUT3
expression in glioma stem cells and bulk glioma cells, and
also inhibited the metabolism, proliferation, and downregulated
further glioma stem cells percentage (Xu C. F. et al., 2015).
Because of the diversity of organic nanoparticles and the
tunability of their properties, they have been exploited extensively
for cancer therapies and will play a bigger role in the
future.
SUMMARY AND OUTLOOK
CSCs, also called as cancer- (or tumor-) initiating cells, are
not only a grand challenge in cancer therapy, but also a great
opportunity for researchers to overcome cancer. CSCs have been
regarded as one of the most possible reasons for the inefficiency
or failure (recurrence andmetastasis) of current cancer therapies,
which can be mainly ascribed to the multidrug resistance,
dormancy and resistance to apoptosis properties of these cells.
All these properties enable them obvious and challenging targets
for improving the present therapeutic approaches. Despite the
challenges, much effort has been devoted to selectively target
CSCs. A wide spectrum of materials, such as carbon, DNA,
metal, polymer has been used in cancer therapy by targeting
CSCs as summarized in Table 1. Each of these materials has
its own unique properties, such as high levels of structural
programmability and addressability of DNA origami, stability,
and tunable optical properties of Au NPs, Electro-conductivity
and large surface area of grapheme and diversity of polymer
NPs, combine several of these materials and take advantage of
these properties will provide better solutions for the targeted and
controlled destruction of CSCs.
The biological structures and functionalities of cancer cells,
especially CSCs, are very complicated, thus it is essential to
explore the exact mechanisms, to further understand their
cell biology, and, most importantly, to find biomarkers and
pathways for the specific targeting and destructing the CSCs. In
a word, the ultimate goal of CSC research is to identify effective
targeting biomarkers, delivering pathways, and therapeutics that
can eliminate CSCs of various cancers, which may be realized
by combining advances in cell biology of CSC and progress in
nanotechnologies. In the future, multifunctional nanosystems
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TABLE 1 | The list of nanoparticles targeting CSC.
Type of nanoparticles Targets Anticancer agent Type of cancer References
Carbon nanomaterials Graphene oxide Six independent
cancer cell lines,
HA receptors
Nanographene oxide, nanographene
oxide-Hyaluronic acid
Breast cancer, ovarian cancer,
prostate cancer, lung cancer,
pancreatic cancer, brain cancer,
melanoma skin cancer
Jung et al., 2014;
Fiorillo et al., 2015
Carbon nanotubes HA receptors,
CD44
Carbon nanotube,
Paclitaxel/SAL(salinomycin)-
SWNT(single wall
carbon nanotubes)-CHI(chitosan)-
HA(hyaluronic
acid)
Breast cancer stem cells, gastric
cancer stem cells
Yao et al., 2014; Al
Faraj et al., 2016a,b
Nanodiamond None Nanodiamond with hyperbranched
polyglycerol with anticancer drug
(dND-PG-Anticancer drug),
Epirubicin@nanodiamonds(EPND)
Hepatic cancer stem cells Wang et al., 2014;
Zhao et al., 2014
DNA origami Triangle, tube etc. None Doxorubicin-DNA nanostructure delivery
platform, rod-like DNA origami
daunorubicin carrier
Human breast cancer cells (MCF 7),
doxorubicin-resistant cancer cells,
leukemia cells exhibiting multi-drug
resistance (MDR)
Jiang et al., 2012;
Halley et al., 2016
Gold nanoparticles Sphere Au NPs None Monolayer L-aspartate Au NPs with drugs,
Au NPs modified with thio-PEG
(polyethylene glycol) and thio-glucose
(Glu-Au NPs), Au NPs modified with
mature miR-182 duplexes
Hepatocellular carcinoma, cancer
metastasis and cancer stem cells,
Glioblastoma multiforme (GBM)
Tomuleasa et al.,
2012; Hu et al.,
2015; Kouri et al.,
2015
Gold nanorods TGF-β,
acid-liable,
ALDH
Polyelectrolyte conjugated Au NRs with
salinomycin (SA)
Aldehyde dehydrogenase positive
(ALDHþ) cells
Wang et al., 2013;
Xu et al., 2014
Organic nanoparticles Liposome NFκB pathway,
CCL-23R,
UM-SCC-1R,
CD44
Lipo-DS/CuGlu, Nano-Taxol,
Curcumin-difluorinated (CDF) liposomes,
monoclonal antibody (mAb) modified doxil,
ESC8 dexamethasone liposome (DXE)
Colon cancer, gastric cancer,
pancreatic cancer, cisplatin resistant
Head and neck squamous cell
carcinoma (HNSCC), breast cancer
stem-cell, aggressive and
drug-resistive tumor progenitor cells
Liu et al., 2014;
Arabi et al., 2015;
Basak et al., 2015;
Shen et al., 2015;
Ahmad et al., 2016
Polymer nanoparticles CD133+, CD44 Nanoparticle-encapsulated inhibitor of the
hedgehog transcription factor(NanoHHI),
acid-functionalized poly(carbonate) and
poly(ethylene glycol) diblock copolymer
(PEG-PAC) and urea-functionalized
poly(carbonate) (PUC) and PEG diblock
copolymer (PEG-PUC), CD133-targeted
nanoparticles (CD133NPs), Cationic
lipid-assisted poly(ethylene
glycol)-b-poly(d,L-lactide) (PEG-PLA)
nanoparticles with specific siRNA targeting
GLUT3 (NPsiGLUT3)
Huh7 and MHCC97L cells,
hepatocellular carcinoma cells (HCC),
doxorubicin resistant cancer stem
cells, CD133+ cells, Caco-2 cells,
U87MG and U251 glioma stem cells
and bulk glioma cells
Xu et al., 2012;
Swaminathan et al.,
2013; Wei et al.,
2013; Ke et al.,
2014; Ni et al.,
2015; Xu C. F. et al.,
2015
would be a solution for the early detection and destruction
of CSCs.
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